KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Deferred Taxes: 2019-2024

Historic Deferred Taxes for Pacira BioSciences (PCRX) over the last 6 years, with Dec 2024 value amounting to $20.6 million.

  • Pacira BioSciences' Deferred Taxes rose 623.95% to $8.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.7 million, marking a year-over-year decrease of 42.11%. This contributed to the annual value of $20.6 million for FY2024, which is 32.06% up from last year.
  • Per Pacira BioSciences' latest filing, its Deferred Taxes stood at $20.6 million for FY2024, which was up 32.06% from $15.6 million recorded in FY2023.
  • Pacira BioSciences' 5-year Deferred Taxes high stood at $20.6 million for FY2024, and its period low was -$126.6 million during FY2020.
  • Over the past 3 years, Pacira BioSciences' median Deferred Taxes value was $15.6 million (recorded in 2023), while the average stood at $9.4 million.
  • Its Deferred Taxes has fluctuated over the past 5 years, first crashed by 6,826.31% in 2020, then spiked by 296.54% in 2023.
  • Yearly analysis of 5 years shows Pacira BioSciences' Deferred Taxes stood at -$126.6 million in 2020, then soared by 108.59% to $10.9 million in 2021, then plummeted by 173.08% to -$7.9 million in 2022, then surged by 296.54% to $15.6 million in 2023, then surged by 32.06% to $20.6 million in 2024.